• Novel Drug Products Creation with new composition-of-Matter IP

    Our technology is a powerful Intellectual Property (IP) engine

Topical therapies are the therapeutic pillar for many diseases, but traditional water- or oil-based formulations have significant limitations that may influence efficacy and safety.

EyeSol® is the worldwide first and only water-free technology for ophthalmic products. It dramatically increases the residual time on the eye from minutes to hours and enables high bioavailability of active pharmaceutical ingredients (API) with excellent tolerability and safety while reducing systemic exposure due to a small drop size (10 µL).

Thereby EyeSol® unlocks the full potential of APIs by generating novel drug products often even with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.

Our products have the potential to redefine drug therapies. Refer to Products or Pipeline for more insight on how EyeSol® overcomes the limitations in eye care therapies

Approved CE products: Novatears®, Novatears®+Omega-3